Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.
Focusing on the unmet medical needs of patients with rare disorders and their families
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Pioneering cannabinoid treatments for neuropsychiatric conditions
Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X SyndromeRead More
Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual MeetingRead More
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual MeetingRead More
Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare ConferenceRead More